GET THE APP

Virology & Mycology

Virology & Mycology
Open Access

ISSN: 2161-0517

+44 1223 790975

Review - (2021)Volume 10, Issue 1

SARS-Cov-2 (COVID-19) Pandemic Outbreak: A Worldwide Challenge and Contemporary Situation

Prashant Swapnil1 and Mukesh Meena2*
 
*Correspondence: Mukesh Meena, Department of Botany, Laboratory of Phytopathology and Microbial Biotechnology, Mohanlal Sukhadia University, Udaipur, Rajasthan, India, Email:

Author info »

Abstract

Objectives: In this review article, the authors carried out a study about the COVID-19 pandemic outbreak, its challenges and current situation in worldwide. This study aimed to determine the morphological characters, genome sequence, symptoms and preventions.

Methodology: The pandemic of COVID-19 has very substantial medical, economic and social consequences. The study was observed during the coronavirus outbreak from December 2019 to till date. In Wuhan, China December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections was found and it has been spreaded across China.

Results: Coronavirus is a pandemic disease and appears major public health anxiety. This is the time to exercise restrains and caution. Whole world’s many governments, scholars and scientists are engaged for discover the proper treatment until we find the proper and right treatment for it we have to be careful to avoid infection.

Conclusion: This paper included origin and morphology of the novel coronavirus and current scenario of disease, cause of disease, symptoms of disease and how to prevent from its infection. WHO officially stated the infection spreaded by a novel coronavirus and named it COVID-19. Presently, whole world is struggling with COVID-19 disease.

Keywords

COVID-19; SARS-CoV; Pandemic; Infection; Symptoms; Prevention

Introduction

On dated December 8th, 2019, the novel SARS-CoV-2 coronavirus that expressed in Wuhan City of Hubei Province of China and became epidemic at large scale. The COVID-19 disease spreaded among more than 210 other countries. In March 2020, around 3300 deaths due to coronavirus and approximate, 96,000 corona positive (COVID-19) cases have been reported in China while in India reported 29 cases [1]. On dated 9th January 2020, coronavirus emerged as novel infectious viral agent [2,3] which has unique background of infection in human being in 1997 due to avian influenza A H5N1 [4] and SARSCoV in 2003 [5]. The origin of this infection was started from china. In Wuhan, the capital city of Hubei, December 2019, adult people started suffering from severe pneumonia-like unknown disease. The respiratory samples of the affected people sent to the labs for etiologic investigations and found the cause of this disease was coronavirus which had more than 95% homology with the bat coronavirus and more than 70% similarity with the SARSCoV which is further notified by World Health Organization (WHO). Many of the cases reported from the Huanan seafood wholesale market which also known to traded live animals. So, the surveillance system was activated after the knowing cause of infection and which signified that the virus was originated from the Huanan seafood market [6]. It has been declared the transmission of virus was found more rapidly by human-to-human contact [7]. Now a day’s, this disease (COVID-19) affected whole world and became anxiety. The epidemiology of this infection stated that the susceptibility of the coronavirus infection was found in all age people. It transmitted through the symptomatic patients to the healthy person by coughing and sneezing in the range of 1-2 m but now it also spread through asymptomatic people [8-10]. The virus can remain viable on surfaces and can be destroyed by some common disinfectants such as hydrogen peroxide, sodium hypochlorite, etc. [11].

Morphology and Genome Sequence Of Coronavirus

Coronaviruses are spherical particles (150 to 160 nm) which is enveloped and pleomorphic, and consist of constructive singlestranded RNA, un-segmented, nucleoprotein, capsid, matrix, and surface glycoprotein (S-protein) (Figure 1). Significant viral proteins comprises different type of proteins such as nucleocapsid protein (N), membrane protein (M), spike glycoprotein (S), and envelope small membrane protein (E). Glycoproteins such as acetyl esterase and Hemagglutination encoded by some beta coronaviruses eg. COVID-19 causing coronaviruses [12-14]. Glycoprotein (S) is the outermost covering of this virion which provides typical shape. Coronavirus name is given due to the homotrimers of these S proteins which resembles sun-like morphologies [15-17]. S proteins interact with the M proteins and virion membrane through C-terminal trans-membrane regions [18,19]. Regeneration of virions in the cell is governed by the M protein. There are three trans-membrane regions was found in M Glycoproteins which goes under modification of the virion to fuse with the cell and to make them antigenic by interacting with Endoplasmic Reticulum -Golgi Apparatus Intermediate Compartment (ERGIC) [20- 25]. Glycoproteins (E) composed of around 76 to 109 amino acids. Amino acids in the N-terminus allow the glycoprotein (E) attachment to the viral membrane [26]. It also helps in the assembly and morphogenesis of virions inside the cell. N proteins are phosphoproteins having a flexible structure of viral genomic RNA by binding to the helix. Due to locating in both the replication or transcriptional regions and the ERGIC region. It plays a key role in virion structure, replication and transcription [22,27-34].

virology-mycology-depiction

Figure 1:Pictorial depiction of the leading structure of crown shaped COVID-19 coronavirus identical to the solar corona due to presence of spikes.

Evaluation of the genome arrangement showed that COVID-19 is more identical with SARS-CoV as compared to MERS-CoV6 and the RNA binding domain of the S-protein of COVID-19 also showed more homology with with SARS-CoV. Depending upon polyprotein and S-protein the arrangement of amino acid in COVID-19 coronavirus is differ from former coronaviruses completely. S-protein (consist two subunits) helps to binding of the coronavirus to the host cells. S protein binds with the receptor of host cell and enters inside the host cell. Most of the studies revealed that angiotensin-converting enzyme (ACE2 and mostly ACE29) works as receptor for the COVID-19 in human [35-37]. It has been noted that specific CoV do not need to have the full ensemble of structural proteins to make virons, highlighting that certain proteins maybe dispensable or compensated by the function of non-structural proteins [38]. Table 1 shows the structural proteins of coronavirus and their functional roles.

STRUCTURAL PROTEINS PROTEINS FUNCTION
Spike glycoprotein (S) Critical for binding of host cell receptors to facilitate entry of host cell
Nucleocapsid protein (N) Bound to RNA genome to make up nucleocapsid
Envelope small membrane protein (E) Interacts with M to form viral envelope
Membrane protein (M) Central organizer of CoV assembly
Determines shape of viral envelope
Hemagglutinin-Esterase (HE) Forms a distinct inner fringe of short peplomer

Table 1: Structural proteins of coronavirus and their functions (Adopted from [26]).

Covid -19 Symptoms

Understanding the symptoms of COVID-19 is a very important aspect. Common symptoms of COVID-19 are including fever, cough, and fatigueness. Few days prior to fever symptoms arises with diarrhea and nausea, it is suggested that fever is dominating symptoms but not the premier symptom of infection. Some patients also can suffer from hemoptysis or headache [39,40] and some even asymptomatic [41]. Severe alveolar damage due to respiratory failure affects commonly older men. The disease shows organ dysfunction such as Acute Respiratory Distress Syndrome (ARDS), shock, acute cardiac and kidney injury and in severe cases, it causes death [7,40]. The COVID-19 positive patients might show lower white blood cell counts, thrombocytopenia or lymphopenia, and increment in C-reactive protein level [7,39,40].

As it is clear through literature investigations, there are situations where patients affirmed with COVID-19 contamination have no chest CT irregularities, appearing differently in relation to subclinical disease giving positive imaging discoveries on CT. It is urgent that the clinical effects of screening asymptomatic patients with chest CT be resolved. A progressively careful examination about the presence of any possible advantage on clinical results should be tended to against the known monetary expenses and presentation to ionizing radiation related with CT checking. Overall, the symptoms of this virus are like pneumonia. According to WHO reports, based on 56, 000 lab cases the fit symptoms of coronavirus infection caused 14%, 5%, 14%, 88%, 5%, 19%, 15%, 38%, 11%, 4%, 33% and 68% of headache, runny nose, sore throat, fever, vomiting, shortness of breath, joint pain fatigue, chills, diarrhea, phlegm, dry cough, respectively.

Spreads Of Coronavirus and Prevention

The human coronavirus (COVID-2019) generally spreads from person to person through open-air coughing and sneezing, touching or shaking hands, touching a narrow object or surface, then touching your nose, eyes or mouth without washing or sanitizing your hands and use of an infected thing like vegetable and other food items. The basic and most important prevention of COVID-19 infections are such as clean your hands with soap and water or alcohol-containing hand bars, cover your nose and mouth with a tissue or bent elbow when coughing and sneezing, avoid making close contact with people who have cold or flu-like symptoms, always allow hello or greet at the place of hand contact, use the mask and dispose of it after using by burning of buried, avoid going to public places and crowds, avoid market food items which are cooked out of the house, after bringing the vegetable, wash it immediately with hot salt water, avoid courier or postal item it may carry the virus infection, do not let the children play or visit outside of the house, always prefer to take more fluids, do not invite guests or other outsiders to the house and also minimize the use of computers, and gadgets used by other persons. The most common target of the infection is elder or aged people so do not let them out of the house. There is one example of prevention is that Indian government put one-day ‘JANTA’ curfew on dated March 22, 2020, for the same. If you feel the symptoms of COVID-19 infection such as fever, cough and difficulty in breathing, immediately contact the doctor and follow the important information, and the advice is given by the doctors.

Existing Situation

According to World Health Organization (WHO) it is a pandemic disease and found 215 countries, areas or territories and till June 17th, 2020 total confirm cases 8,295,151, confirmed deaths 446,746 and recovered cases are 4,346,863. In India, total of 155,227 cases are confirmed out of 11,903 death and 186,934 get recovered till June 17th, 2020. The highest confirmed in Maharashtra state which is 113,445 and deceased 5,537. Here, we presented the worldwide report of confirmed cases and deaths by country, territory, or conveyance.

Confirmed Coronavirus Cases and Deaths By Country and Territory Or Conveyance

The coronavirus COVID-19 is affecting 213 countries and territories around the world and 2 international conveyances: the Diamond Princess Cruise ship harbored in Yokohama, Japan, and Holland America's MS Zaandam cruise ship. The day (June 17, 2020) is reset after midnight UTC+7. The list of countries and territories and their continental regional classification is based on the Countrycodex.COVID-19 affected countries report of coronavirus cases in globally (Table 2).

S. No. Country, Other Total Cases Total Deaths    Total Recovered Active Cases Total Tests Population
World 82,95,151 4,46,746 43,46,863 35,01,542    
1 USA 22,08,787 1,19,145 9,03,136 11,86,506 2,57,30,914 33,09,28,170
2 Brazil 9,28,834 45,456 4,77,364 4,06,014 17,09,468 21,25,00,470
3 Russia 5,53,301 7,478 3,04,342 2,41,481 1,56,79,724 14,59,32,234
4 India 3,55,060 11,922 1,87,718 1,55,420 60,84,256 1,37,94,55,941
5 UK 2,98,136 41,969 N/A N/A 69,81,493 6,78,72,439
6 Spain 2,91,408 27,136 N/A N/A 48,26,516 4,67,54,133
7 Italy 2,37,500 34,405 1,78,526 24,569 46,95,707 6,04,64,907
8 Peru 2,37,156 7,056 1,25,205 1,04,895 13,96,605 3,29,52,301
9 Iran 1,95,051 9,185 1,54,812 31,054 13,19,920 8,39,47,823
10 Germany 1,88,523 8,910 1,73,600 6,013 46,94,147 8,37,74,027
11 Chile 1,84,449 3,383 1,56,232 24,834 8,73,533 1,91,09,674
12 Turkey 1,81,298 4,842 1,53,379 23,077 27,21,003 8,43,01,943
13 France 1,57,716 29,547 73,335 54,834 13,84,633 6,52,68,238
14 Mexico 1,54,863 18,310 1,16,178 20,375 4,28,563 12,88,77,519
15 Pakistan 1,54,760 2,975 58,437 93,348 9,50,782 22,06,97,198
16 Saudi Arabia 1,41,234 1,091 91,662 48,481 11,44,282 3,47,90,318
17 Canada 99,467 8,213 61,443 29,811 22,16,730 3,77,28,960
18 Bangladesh 98,489 1,305 38,189 58,995 5,51,244 16,46,22,947
19 China 83,265 4,634 78,379 252   1,43,93,23,776
20 Qatar 83,174 82 62,172 20,920 3,04,801 28,07,805
21 South Africa 76,334 1,625 42,063 32,646 11,72,513 5,92,77,377
22 Belgium 60,244 9,675 16,684 33,885 10,56,075 1,15,87,727
23 Belarus 56,032 324 32,735 22,973 7,78,935 94,49,432
24 Colombia 54,931 1,801 20,366 32,764 5,19,990 5,08,60,734
25 Sweden 53,323 4,939 N/A N/A 3,25,000 1,00,96,837
26 Netherlands 49,204 6,074 N/A N/A 4,84,389 1,71,33,488
27 Ecuador 47,943 3,970 23,684 20,289 1,35,845 1,76,31,471
28 Egypt 47,856 1,766 12,730 33,360 1,35,000 10,22,47,168
29 UAE 42,982 293 28,861 13,828 26,26,000 98,85,431
30 Indonesia 41,431 2,276 16,243 22,912 5,59,872 27,34,05,579
31 Singapore 41,216 26 31,163 10,027 5,76,189 58,48,529
32 Portugal 37,672 1,523 23,580 12,569 10,06,563 1,01,97,718
33 Kuwait 37,533 306 28,896 8,331 3,43,027 42,67,854
34 Argentina 34,159 878 10,174 23,107 2,45,059 4,51,79,151
35 Ukraine 33,234 943 14,943 17,348 5,17,995 4,37,42,277
36 Switzerland 31,183 1,956 28,900 327 4,75,224 86,52,146
37 Poland 30,701 1,286 14,921 14,494 12,47,099 3,78,48,055
38 Philippines 27,238 1,108 6,820 19,310 5,26,100 10,95,19,465
39 Afghanistan 26,874 504 6,158 20,212 60,298 3,88,86,984
40 Oman 26,079 116 11,797 14,166 1,48,467 51,00,291
41 Ireland 25,334 1,709 22,698 927 3,86,572 49,35,518
42 Dominican
Republic
23,686 615 14,133 8,938 1,12,603 1,08,43,502
43 Romania 22,760 1,451 16,117 5,192 5,85,353 1,92,41,808
44 Iraq 22,700 712 9,862 12,126 3,80,005 4,01,79,950
45 Panama 21,962 457 13,774 7,731 93,646 43,11,810
46 Bolivia 19,883 659 3,752 15,472 47,372 1,16,66,267
47 Israel 19,637 303 15,459 3,875 7,88,870 91,97,590
48 Bahrain 19,553 48 13,866 5,639 4,38,080 16,98,380
49 Armenia 18,033 302 6,814 10,917 87,600 29,63,042
50 Japan 17,587 927 15,701 959 3,44,526 12,64,89,572
51 Austria 17,203 687 16,099 417 5,40,615 90,04,430
52 Nigeria 17,148 455 5,623 11,070 96,402 20,58,92,211
53 Kazakhstan 15,542 88 9,716 5,738 11,84,416 1,87,67,378
54 Serbia 12,426 256 11,511 659 3,13,483 87,38,546
55 Denmark 12,294 598 11,185 511 8,40,721 57,91,444
56 Moldova 12,254 427 7,077 4,750 63,328 40,34,284
57 S. Korea 12,198 279 10,774 1,145 11,32,823 5,12,67,604
58 Ghana 12,193 58 4,326 7,809 2,55,971 3,10,42,920
59 Algeria 11,147 788 7,842 2,517   4,38,15,597
60 Guatemala 10,706 418 2,096 8,192 31,427 1,79,00,654
61 Azerbaijan 10,662 126 5,948 4,588 3,86,898 1,01,35,522
62 Czechia 10,112 332 7,360 2,420 5,05,272 1,07,08,259
63 Cameroon 9,864 276 5,570 4,018   2,65,13,830
64 Honduras 9,656 330 1,075 8,251 21,540 98,97,736
65 Morocco 8,985 212 7,960 813 4,63,157 3,68,92,413
66 Norway 8,660 242 8,138 280 2,85,867 54,19,572
67 Malaysia 8,515 121 7,873 521 6,64,334 3,23,48,590
68 Sudan 7,740 477 2,820 4,443 401 4,38,00,496
69 Australia 7,370 102 6,859 409 18,77,702 2,54,87,651
70 Nepal 7,177 20 1,167 5,990 3,83,315 2,91,13,368
71 Finland 7,117 326 6,200 591 2,24,400 55,40,409
72 Ivory Coast 5,679 46 2,637 2,996 38,637 2,63,46,655
73 Uzbekistan 5,638 19 4,096 1,523 7,48,555 3,34,48,409
74 Senegal 5,369 73 3,606 1,690 63,862 1,67,22,182
75 Tajikistan 5,160 50 3,624 1,486   95,27,545
76 DRC 5,100 115 640 4,345   8,94,21,061
77 Guinea 4,639 26 3,327 1,286 14,407 1,31,15,087
78 Haiti 4,547 80 24 4,443 9,353 1,13,96,738
79 Djibouti 4,539 43 3,324 1,172 40,855 9,87,384
80 North Macedonia 4,482 210 1,803 2,469 46,445 20,83,377
81 Gabon 4,114 29 1,432 2,653 23,741 22,23,225
82 Hungary 4,078 567 2,547 964 2,42,139 96,61,188
83 Luxembourg 4,075 110 3,933 32 1,16,869 6,25,532
84 El Salvador 4,066 78 2,137 1,851 1,30,677 64,84,963
85 Kenya 3,860 105 1,328 2,427 1,21,956 5,37,15,735
86 Ethiopia 3,630 61 738 2,831 1,92,087 11,48,25,733
87 Bulgaria 3,453 181 1,817 1,455 1,08,325 69,50,101
88 Venezuela 3,150 27 835 2,288 10,81,542 2,84,38,678
89 Greece 3,148 185 1,374 1,589 2,59,736 1,04,24,732
90 Thailand 3,135 58 2,996 81 4,68,175 6,97,93,557
91 Bosnia and Herzegovina 3,085 168 2,178 739 77,494 32,81,478
92 Somalia 2,658 88 649 1,921   1,58,70,989
93 Kyrgyzstan 2,562 30 1,902 630 1,50,612 65,19,466
94 CAR 2,410 14 396 2,000 18,921 48,26,038
95 Mayotte 2,333 29 2,058 246 8,800 2,72,499
96 Cuba 2,273 84 1,994 195 1,38,831 1,13,26,859
97 Croatia 2,258 107 2,141 10 70,712 41,06,085
98 Maldives 2,094 8 1,670 416 35,533 5,40,120
99 Mauritania 2,057 93 373 1,591 13,842 46,43,639
100 Estonia 1,977 69 1,743 165 99,000 13,26,503
101 Sri Lanka 1,921 11 1,397 513 90,010 2,14,09,881
102 Mali 1,885 106 1,145 634 9,873 2,02,21,292
103 Nicaragua 1,823 64 1,238 521   66,21,283
104 Iceland 1,812 10 1,796 6 63,198 3,41,157
105 Costa Rica 1,796 12 794 990 32,801 50,92,255
106 Lithuania 1,778 76 1,447 255 3,75,572 27,23,374
107 South Sudan 1,776 30 58 1,688 3,356 1,11,88,290
108 Albania 1,722 38 1,077 607 19,266 28,77,906
109 Equatorial Guinea 1,664 32 515 1,117 16,000 14,00,545
110 Slovakia 1,561 28 1,437 96 1,98,780 54,59,548
111 New Zealand 1,506 22 1,482 2 3,16,251 50,02,100
112 Slovenia 1,503 109 1,359 35 90,519 20,78,928
113 Guinea-Bissau 1,492 15 153 1,324 1,500 19,65,778
114 Lebanon 1,473 32 889 552 1,08,039 68,26,459
115 French Guiana 1,421 5 619 797 277 2,98,302
116 Zambia 1,405 11 1,142 252 45,248 1,83,58,109
117 Madagascar 1,378 12 450 916 16,402 2,76,56,188
118 Paraguay 1,303 13 699 591 49,978 71,28,884
119 Sierra Leone 1,225 51 686 488   79,69,522
120 Tunisia 1,125 49 1,002 74 61,430 1,18,13,579
121 Hong Kong 1,121 4 1,071 46 2,75,293 74,94,577
122 Latvia 1,104 30 875 199 1,31,646 18,86,823
123 Niger 1,016 66 885 65 6,317 2,41,58,588
124 Cyprus 985 18 816 151 1,42,912 12,07,015
125 Jordan 981 9 693 279 2,92,623 1,01,99,034
126 Burkina Faso 895 53 809 33   2,08,74,685
127 Georgia 888 14 731 143 78,158 39,89,431
128 Yemen 885 214 91 580 120 2,97,95,150
129 Congo 883 27 391 465   55,11,524
130 Andorra 854 52 789 13 3,750 77,261
131 Chad 853 74 720 59   1,64,02,021
132 Uruguay 849 24 801 24 54,486 34,73,283
133 Cabo Verde 781 7 354 420 1,307 5,55,740
134 Uganda 732   420 312 1,53,180 4,56,65,591
135 Diamond Princess 712 13 651 48    
136 San Marino 696 42 591 63 5,433 33,928
137 Sao Tome and Principe 671 12 182 477 1,464 2,18,976
138 Malta 662 9 610 43 84,964 4,41,500
139 Mozambique 638 4 160 474 20,263 3,12,11,470
140 Rwanda 636 2 338 296 96,801 1,29,36,672
141 Jamaica 621 10 449 162 16,947 29,60,681
142 Benin 572 9 237 326 46,622 1,21,07,579
143 Channel Islands 568 48 512 8 10,255 1,73,799
144 Malawi 564 6 73 485 8,523 1,91,05,730
145 Togo 537 13 344 180 25,589 82,69,473
146 Eswatini 520 4 259 257 6,551 11,59,675
147 Palestine 514 3 415 96 44,876 50,95,772
148 Liberia 509 33 222 254   50,52,009
149 Tanzania 509 21 183 305   5,96,48,351
150 Réunion 495 1 460 34 17,200 8,95,063
151 Libya 484 10 76 398 14,029 68,67,331
152 Taiwan 445 7 434 4 74,699 2,38,15,210
153 Zimbabwe 391 4 62 325 52,905 1,48,53,642
154 Mauritius 337 10 325 2 1,37,789 12,71,692
155 Isle of Man 336 24 312 0 5,620 85,016
156 Vietnam 335   325 10 2,75,000 9,73,03,556
157 Montenegro 326 9 315 2 13,186 6,28,063
158 Myanmar 262 6 179 77 53,351 5,43,95,646
159 Suriname 236 6 48 182 1,165 5,86,422
160 Martinique 202 14 98 90   3,75,275
161 Comoros 197 3 127 67   8,68,739
162 Mongolia 197   111 86 18,886 32,75,982
163 Cayman Islands 193 1 123 69 18,220 65,690
164 Faeroe Islands 187   187 0 11,162 48,856
165 Syria 177 6 78 93   1,74,80,189
166 Gibraltar 176   176 0 10,428 33,691
167 Guadeloupe 171 14 157 0 5,691 4,00,122
168 Guyana 171 12 99 60 1,995 7,86,408
169 Angola 148 6 64 78 10,000 3,28,13,171
170 Bermuda 144 9 128 7 9,246 62,286
171 Brunei 141 3 138 0 25,600 4,37,310
172 Cambodia 128   126 2 28,524 1,67,09,126
173 Trinidad and Tobago 123 8 109 6 4,111 13,99,320
174 Eritrea 121   39 82   35,44,334
175 Bahamas 104 11 72 21 2,261 3,93,093
176 Burundi 104 1 75 28 382 1,18,72,654
177 Aruba 101 3 98 0 2,233 1,06,749
178 Monaco 99 4 94 1 16,200 39,231
179 Barbados 97 7 83 7 6,960 2,87,362
180 Liechtenstein 82 1 55 26 900 38,124
181 Sint Maarten 77 15 62 0 477 42,856
182 Bhutan 67   24 43 21,790 7,71,259
183 Botswana 60 1 24 35 26,800 23,49,447
184 French Polynesia 60   60 0 4,578 2,80,846
185 Macao 45   45 0   6,48,960
186 Saint Martin 42 3 36 3 685 38,637
187 Gambia 34 1 24 9 1,970 24,13,256
188 Namibia 34   18 16 5,919 25,38,844
189 St. Vincent Grenadines 29   25 4 731 1,10,927
190 Antigua and Barbuda 26 3 22 1 489 97,897
191 Timor-Leste 24   24 0 1,568 13,17,308
192 Curaçao 23 1 19 3 1,080 1,64,068
193 Grenada 23   22 1 4,130 1,12,503
194 Belize 22 2 16 4 1,957 3,97,304
195 New Caledonia 21   21 0 7,788 2,85,387
196 Laos 19   19 0 11,249 72,71,033
197 Saint Lucia 19   18 1 1,356 1,83,595
198 Dominica 18   16 2 534 71,979
199 Fiji 18   18 0 2,431 8,96,191
200 Saint Kitts and Nevis 15   15 0 417 53,184
201 Falkland Islands 13   13 0 671 3,475
202 Greenland 13   13 0 2,723 56,766
203 Turks and Caicos 12 1 11 0 245 38,695
204 Vatican City 12   12 0   801
205 Montserrat 11 1 10 0 61 4,992
206 Seychelles 11   11 0   98,324
207 MS Zaandam 9 2   7    
208 Western Sahara 9 1 8 0   5,96,630
209 British Virgin Islands 8 1 7 0 212 30,223
210 Papua New Guinea 8   8 0 5,281 89,39,356
211 Caribbean Netherlands 7   7 0 424 26,213
212 St. Barth 6   6 0 152 9,876
213 Lesotho 4   2 2 1,515 21,41,579
214 Anguilla 3   3 0 93 14,998
215 Saint Pierre Miquelon 1   1 0   5,795
   Total 8295151 446746 4346863 3501542  

Table 2: COVID-19 affected countries report of total coronavirus cases, total deaths; total recovered and total active cases (Data obtained from June 17, 2020).

Conclusion

Through this review article, we infer that the disease framework of COVID-19 is dynamic and proceeds to quickly spread. The COVID-19 pandemic is dispersing transversely the world at a disturbing recurrence. It has caused more infections and deceases as contrasted to SARS and MERS. There are hitherto many open quarries that are pending about COVID-19. Maturing and immunocompromised patients are at the extraordinary danger of mortality. The brief degree of disease licenses exceptional examination and quarantine protocols to prevent further transmission. Till date, no prolonged drug or immunization has been created. Present treatment approaches are expected at symptomatic precaution and oxygen rehabilitation. In future, prophylactic vaccination will be obligatory for the impending prevention of COV-associated epidemic or pandemic.

Conflict Of Interest Statement

None declared

Funding Sources

There is no funding source available.

Authors's Contributions

MM and PS contributed to all chapters and had a key role in formulating the review. PS and MM wrote review, critically read and corrected the entire manuscript, and MM adjusted it to the required format. MM prepared the figures and the list of references.

References

  1. Cheng VCC, Wong SC, To KKW, Ho P L, Yuen K-Y . Preparedness and proactive infection control measures against the emerging novel corona virus in China. J Hosp Infect. 2020; 104(2020):254-55.
  2. Kristian G. Andersen, Andrew Rambaut, W. Ian Lipkin, Edward C. Holmes, Robert F. Garry. The proximal origin of SARS-CoV-2. Nate Med. 2020.
  3. Yuen KY, Chan PK, Peiris M, Tsang  D N,  Que T L, Shortridge K F, Cheung P T, et al. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. The Lancet 1998;351:467e71.
  4. Cheng VC, Lau SK, Woo PC, Yuen KY. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin Microbiol Rev. 2007;20:660e94.
  5. Huaxia. Chinaâ??s CDC detects a large number of new coronaviruses in the South China seafood market in Wuhan. 2020.
  6. Huang C, Wang Y, Li X,  Ren L,  Zhao J,  Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(10223):497-506
  7. Rothe C, Schunk M, Sothmann P, Bretzel G ,  Froeschl G , Wallrauch C , et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med. 2020;382(10):970-1.
  8. Zou L, Ruan F, Huang M, Liang L , Huang H , Hong  Z  et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020;382(12):1177-9
  9. Kampf G, Todt D, Pfaender S, Steinmann  E . Persistence of coronaviruses on inanimate surfaces and its inactivation with biocidal agents. J Hosp Infect. 2020;S0195â??6701(20)30046â??3.
  10. Lissenberg A, Vrolijk MM, van Vliet AL, Langereis M A,  Groot-Mijnes JDF ,  Rottier PJM,  et al. Luxury at a cost? Recombinant mouse hepatitis viruses expressing the accessory hem agglutinin esterase protein display reduced fitness in vitro. J Virol. 2005;79:15054-63
  11. Kannan S, Shaik Syed Ali P, Sheeza A, Hemalatha K. COVID-19 (Novel Coronavirus 2019) â?? recent trends. Eur Rev Med Pharmaco Sci. 2020; 24:2006-11.
  12. Read JM, Bridgen JR, Cummings DA, Ho A,  Jewell C P. Novel coronavirus 2019-nCoV: early estimation of epidemiological parameters and epidemic predictions. medRxiv. 2020
  13. Tan YJ, Lim SG, Hong W. Characterization of viral proteins encoded by the SARS-coronavirus genome. Antiviral Res. 2005;65:69-78
  14. Bárcena M, Oostergetel GT, Bartelink W, Faas FGA,  Verkleij A, Rottier PJM, et al. Cryo-electron tomography of mouse hepatitis virus: Insights into the structure of the coronavirion. Proc Natl Acad Sci USA. 2009;106:582-7
  15. Graham RL, Baric RS. Recombination, reservoirs, and the modular spike: mechanisms of coronavirus cross-species transmission. J Virol. 2010;84:3134-46
  16. Lewicki DN, Gallagher TM. Quaternary structure of coronavirus spikes in complex with carcinoembryonic antigen- related cell adhesion molecule cellular receptors. J Biol Chem. 2002;277:19727-34
  17. Tok TT, Tatar G. Structures and functions of coronavirus proteins: Molecular modeling of viral nucleoprotein. Int J Virol Infect Dis. 2017;2(1):001-007.
  18. Alexander S, Elder JH. Carbohydrate dramatically infl uences immune reactivity of antisera to viral glycoprotein antigens. Science. 1984;226:1328-30
  19. de Haan CA, Kuo L, Masters PS, Vennema H, Rottier P J. Coronavirus particle assembly: primary structure requirements of the membrane protein. J Virol. 1998;72(8):6838-50
  20. Escors D, Ortego J, Enjuanes L. The membrane M protein of the transmissible gastroenteritis coronavirus binds to the internal core through the carboxyterminus. Adv Exp Med Biol. 2001;494:589-93
  21. Narayanan K, Makino S. Characterization of nucleocapsid-M protein interaction in murine coronavirus. Adv Exp Med Biol. 2001;494:577-82
  22. de Haan CA, de Wit M, Kuo L, Montalto-Morrison C, Haagmans B L, Weiss S R , et al. The glycosylation status of the murine hepatitis coronavirus M protein aff ects the interferogenic capacity of the virus in vitro and its ability to replicate in the liver but not the brain. Virology. 2003;312:395-406
  23. Wissink EH, Kroese MV, Maneschijn Bonsing JG, Meulenberg JJM, Rijn PA, Rijsewijk FAM, et al. Significance of the oligosaccharides of the porcine reproductive and respiratory syndrome virus glycoproteins GP2a and GP5 for infectious virus production. J Gen Virol. 2004;85:3715-23
  24. Barupal T, Tak PK, Meena M. COVID-19: Morphology, characteristics, symptoms, prevention, clinical diagnosis and current scenario. Coronaviruses. 2020;1(1);82-9
  25. Bos EC, Luytjes W, van der Meulen HV, Koerten H K , Spaan W J, et al. The production of recombinant infectious DI-particles of a murine coronavirus in the absence of helper virus. Virology. 1996;218:52-60
  26. Vennema H, Godeke GJ, Rossen JW, Voorhout WF, Horzinek MC, Opstelten DJ, et al. Nucleocapsid-independent assembly of coronavirus-like particles by co-expression of viral envelope protein genes. EMBO J. 1996;15:2020-8.
  27. Baudoux P, Carrat C, Besnardeau L, Charley B, Laude H. Coronavirus pseudo particles formed with recombinant M and E proteins induce alpha interferon synthesis by leukocytes. J Virol. 1998;72:8636-43
  28. Raamsman MJB, Locker JK, de Hooge A, Vries AA,  Griffiths G, Vennema H, et al. Characterization of the coronavirus mouse hepatitis virus strain A59 small membrane protein E. J Virol. 2000;74:2333-42
  29. Narayanan K, Makino S. Characterization of nucleocapsid-M protein interaction in murine coronavirus. Adv Exp Med Biol. 2001;494:577-82.
  30. Kuo L, Masters PS. The small envelope protein E is not essential for murine coronavirus replication. J Virol. 2003;77:4597-4608.
  31. DeDiego ML, Alvarez E, Almazan F, Rejas MT,  Lamirande E,  Roberts A , et al. A severe acute respiratory syndrome coronavirus that lacks the E gene is attenuated in vitro and in vivo. J Virol. 2007;81:1701-13.
  32. Stertz S, Reichelt M, Spiegel M, Kuri T, Sobrido LM, Sastre AG, et al. The intracellular sites of early replication and budding of SARS coronavirus. Virology. 2007;361:304-15
  33. Letko M, Munster V. Functional assessment of cell entry and receptor usage for lineage B β-coronaviruses, including 2019-nCoV. bioRxiv. 2020
  34. Sharma S, Swapnil P and Meena M. A Novel 2019 Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19) as Global Pandemic. Cell Cellular Life Sci J. 2020;5(2):000154
  35. Zhao Y, Zhao Z, Wang Y, Zhou Y,  Ma Yu,  Zuo W. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. bioRxiv. 2020.
  36. Mahase E. China Coronavirus: what do we know so far? BMJ. 2020;368:m308.
  37. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of 2019 novel coronavirus infection in China. medRxiv. 2020.
  38. Wang D, Hu B, Hu C, Zhu F, Liu X , Zhang J et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirusâ??infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-1069
  39. Chan JFW, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. The Lancet. 2020;395(10223):514-23.
  40. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet. 2020;pii:S0140-6736(20)30211-7

Author Info

Prashant Swapnil1 and Mukesh Meena2*
 
1Department of Botany, Acharya Narendra Dev College, University of Delhi, New Delhi, India
2Department of Botany, Laboratory of Phytopathology and Microbial Biotechnology, Mohanlal Sukhadia University, Udaipur, Rajasthan, India
 

Citation: Swapnil P, Meena M. (2021) SARS-CoV-2 (COVID-19) Pandemic Outbreak: A Worldwide Challenge and Contemporary Situation. Virol Mycol. 10:201.

Received: 08-Jan-2021 Accepted: 22-Jan-2021 Published: 29-Jan-2021 , DOI: 10.35248/2161-0517.21.10.201

Copyright: © 2021 Meena M et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Sources of funding : NO

Top